In case you missed it, our latest whitepaper provides a practical guide to closing the rare disease product timeline gap; evidence transportability, external control arms, sample-size preservation in real-world evidence, and where to invest early. buff.ly/rlXt6uf
#EUHTA #JCA #OrphanDrug #RWE
#EUHTA #JCA #OrphanDrug #RWE
September 9, 2026 at 10:02 AM
In case you missed it, our latest whitepaper provides a practical guide to closing the rare disease product timeline gap; evidence transportability, external control arms, sample-size preservation in real-world evidence, and where to invest early. buff.ly/rlXt6uf
#EUHTA #JCA #OrphanDrug #RWE
#EUHTA #JCA #OrphanDrug #RWE
If you're developing a therapy for a rare disease, we recommend you check out our new whitepaper, a practical guide to closing that gap: evidence transportability, external control arms, sample-size preservation in #RWE, and where to invest early. buff.ly/rlXt6uf
#EUHTA #JCA #OrphanDrug
#EUHTA #JCA #OrphanDrug
August 21, 2026 at 10:00 AM
If you're developing a therapy for a rare disease, we recommend you check out our new whitepaper, a practical guide to closing that gap: evidence transportability, external control arms, sample-size preservation in #RWE, and where to invest early. buff.ly/rlXt6uf
#EUHTA #JCA #OrphanDrug
#EUHTA #JCA #OrphanDrug
From 2028, orphan drugs face EU JCA built on RCTs, validated endpoints, and standard of care rare diseases rarely have. Read our new whitepaper exploring how to build a defensible evidence package anyway.
lumanity.com/perspectives...
#EUHTA #JCA #orphandrug
lumanity.com/perspectives...
#EUHTA #JCA #orphandrug
July 28, 2026 at 11:00 AM
From 2028, orphan drugs face EU JCA built on RCTs, validated endpoints, and standard of care rare diseases rarely have. Read our new whitepaper exploring how to build a defensible evidence package anyway.
lumanity.com/perspectives...
#EUHTA #JCA #orphandrug
lumanity.com/perspectives...
#EUHTA #JCA #orphandrug
Joint Clinical Assessment leads Brussels: HTACG Itvisma SMA JCA + AI rules; RSV + open CHMP/NICE.
https://europepharmatoday.com/news/htacg-endorses-itvisma-onasemnogene-jca-july-2026?utm_source=bluesky&utm_medium=social&utm_campaign=htacg-endorses-itvisma-onasemnogene-jca-july-2026
#EUHTA
https://europepharmatoday.com/news/htacg-endorses-itvisma-onasemnogene-jca-july-2026?utm_source=bluesky&utm_medium=social&utm_campaign=htacg-endorses-itvisma-onasemnogene-jca-july-2026
#EUHTA
July 20, 2026 at 5:57 AM
Joint Clinical Assessment leads Brussels: HTACG Itvisma SMA JCA + AI rules; RSV + open CHMP/NICE.
https://europepharmatoday.com/news/htacg-endorses-itvisma-onasemnogene-jca-july-2026?utm_source=bluesky&utm_medium=social&utm_campaign=htacg-endorses-itvisma-onasemnogene-jca-july-2026
#EUHTA
https://europepharmatoday.com/news/htacg-endorses-itvisma-onasemnogene-jca-july-2026?utm_source=bluesky&utm_medium=social&utm_campaign=htacg-endorses-itvisma-onasemnogene-jca-july-2026
#EUHTA
Launching in Europe now requires more than regulatory approval. Discover how AI-powered Continuous Intelligence helps improve EU HTA readiness, reimbursement planning, and market access.
Read more:
www.apothiumai.com/Case-Studies...
#EUHTA #Pharma #HealthTech #LifeSciences #AI #ApothiumAI
Read more:
www.apothiumai.com/Case-Studies...
#EUHTA #Pharma #HealthTech #LifeSciences #AI #ApothiumAI
July 2, 2026 at 6:08 AM
Launching in Europe now requires more than regulatory approval. Discover how AI-powered Continuous Intelligence helps improve EU HTA readiness, reimbursement planning, and market access.
Read more:
www.apothiumai.com/Case-Studies...
#EUHTA #Pharma #HealthTech #LifeSciences #AI #ApothiumAI
Read more:
www.apothiumai.com/Case-Studies...
#EUHTA #Pharma #HealthTech #LifeSciences #AI #ApothiumAI
Five early signals from EU HTA implementation in Ireland.
From technical JCA dossiers and Irish-relevant PICOs, to NCPE as Lead Assessor, emerging JCA-specific templates, and the wider value of JCA evidence beyond benefit assessment.
Full details here: bit.ly/4e9qAlw
#EUHTA #SalutemInsights
From technical JCA dossiers and Irish-relevant PICOs, to NCPE as Lead Assessor, emerging JCA-specific templates, and the wider value of JCA evidence beyond benefit assessment.
Full details here: bit.ly/4e9qAlw
#EUHTA #SalutemInsights
June 8, 2026 at 1:49 PM
Five early signals from EU HTA implementation in Ireland.
From technical JCA dossiers and Irish-relevant PICOs, to NCPE as Lead Assessor, emerging JCA-specific templates, and the wider value of JCA evidence beyond benefit assessment.
Full details here: bit.ly/4e9qAlw
#EUHTA #SalutemInsights
From technical JCA dossiers and Irish-relevant PICOs, to NCPE as Lead Assessor, emerging JCA-specific templates, and the wider value of JCA evidence beyond benefit assessment.
Full details here: bit.ly/4e9qAlw
#EUHTA #SalutemInsights
Access Briefing Q1 2026 (EU partner network) is out.
14 countries + Canada, with an Ireland update from Salutem. If you work in HTA/market access and want the quarterly bulletin, full details + subscribe link are in our LinkedIn post: www.linkedin.com/feed/update/...
14 countries + Canada, with an Ireland update from Salutem. If you work in HTA/market access and want the quarterly bulletin, full details + subscribe link are in our LinkedIn post: www.linkedin.com/feed/update/...
#saluteminsights #accessushealth #eupartners #hta #euhta | Salutem Insights Ltd.
⏰ ℹ️ A reminder that the quarterly Access Briefing with our European partners is now available. It contains HTA insights for Q1 2026 from 14 countries across Europe and Canada, including Salutem anal...
www.linkedin.com
May 27, 2026 at 8:55 PM
Access Briefing Q1 2026 (EU partner network) is out.
14 countries + Canada, with an Ireland update from Salutem. If you work in HTA/market access and want the quarterly bulletin, full details + subscribe link are in our LinkedIn post: www.linkedin.com/feed/update/...
14 countries + Canada, with an Ireland update from Salutem. If you work in HTA/market access and want the quarterly bulletin, full details + subscribe link are in our LinkedIn post: www.linkedin.com/feed/update/...
First #JCA was completed under the #EUHTA Regulation with Ireland, member of the Beneluxa Initiative, in the assessor role. Congratulations to #NCPE and @iqwig.bsky.social on reaching this milestone! At the Beneluxa Initiative, we now look into how we can incorporate JCAs into our joint processes.
May 12, 2026 at 9:12 AM
First #JCA was completed under the #EUHTA Regulation with Ireland, member of the Beneluxa Initiative, in the assessor role. Congratulations to #NCPE and @iqwig.bsky.social on reaching this milestone! At the Beneluxa Initiative, we now look into how we can incorporate JCAs into our joint processes.
#RareDisease outcome assessment under #EUHTA and #JointClinicalAssessment | Becaris Publishing becarispublishing.com/digital-cont...
Rare disease outcome assessment under EU HTA and joint clinical assessment | Becaris Publishing
becarispublishing.com
February 5, 2026 at 1:58 PM
#RareDisease outcome assessment under #EUHTA and #JointClinicalAssessment | Becaris Publishing becarispublishing.com/digital-cont...
📣 A new article is out in the Journal of Market Access & Health Policy as part of the Special Issue on #EUHTA.
Authored by our Treatment Access Team, it highlights why patients’ lived experience must be central throughout the EU HTA process.
👉: https://go.eurordis.org/HTAarticle
Authored by our Treatment Access Team, it highlights why patients’ lived experience must be central throughout the EU HTA process.
👉: https://go.eurordis.org/HTAarticle
January 18, 2026 at 8:00 AM
📣 A new article is out in the Journal of Market Access & Health Policy as part of the Special Issue on #EUHTA.
Authored by our Treatment Access Team, it highlights why patients’ lived experience must be central throughout the EU HTA process.
👉: https://go.eurordis.org/HTAarticle
Authored by our Treatment Access Team, it highlights why patients’ lived experience must be central throughout the EU HTA process.
👉: https://go.eurordis.org/HTAarticle
📢 Report Now Available!
CPE and @pce-europe.bsky.social hosted a webinar exploring how the new #EUHTA Regulation can help bridge the gap between policy and real-world access to innovative therapies.
📄 The full report is now available: lnkd.in/enG5RNzz
CPE and @pce-europe.bsky.social hosted a webinar exploring how the new #EUHTA Regulation can help bridge the gap between policy and real-world access to innovative therapies.
📄 The full report is now available: lnkd.in/enG5RNzz
December 30, 2025 at 2:49 PM
📢 Report Now Available!
CPE and @pce-europe.bsky.social hosted a webinar exploring how the new #EUHTA Regulation can help bridge the gap between policy and real-world access to innovative therapies.
📄 The full report is now available: lnkd.in/enG5RNzz
CPE and @pce-europe.bsky.social hosted a webinar exploring how the new #EUHTA Regulation can help bridge the gap between policy and real-world access to innovative therapies.
📄 The full report is now available: lnkd.in/enG5RNzz
La implementación de la #EvaluaciónClínicaConjunta bajo la normativa #EUHTA plantea desafíos en el acceso a tratamientos para #enfermedades raras.
Accede al artículo completo de Félix Rubial en la revista #newsRare👇
bit.ly/4hPyLD9
Accede al artículo completo de Félix Rubial en la revista #newsRare👇
bit.ly/4hPyLD9
December 7, 2025 at 8:16 PM
La implementación de la #EvaluaciónClínicaConjunta bajo la normativa #EUHTA plantea desafíos en el acceso a tratamientos para #enfermedades raras.
Accede al artículo completo de Félix Rubial en la revista #newsRare👇
bit.ly/4hPyLD9
Accede al artículo completo de Félix Rubial en la revista #newsRare👇
bit.ly/4hPyLD9
🩺 𝗘𝘂𝗿𝗼𝗽ä𝗶𝘀𝗰𝗵𝗲 𝗚𝗲𝘀𝘂𝗻𝗱𝗵𝗲𝗶𝘁𝘀𝗱𝗮𝘁𝗲𝗻 𝘂𝗻𝗱 𝗘𝗨-𝗡𝘂𝘁𝘇𝗲𝗻𝗯𝗲𝘄𝗲𝗿𝘁𝘂𝗻𝗴: 𝗪𝗶𝗲 𝗽𝗿𝗼𝗳𝗶𝘁𝗶𝗲𝗿𝗲𝗻 𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝗶𝗻𝗻𝗲𝗻 𝘂𝗻𝗱 𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝗲𝗻?
Aus Sicht der AWMF ist insbesondere die Qualität der Daten im EHDS entscheidend.
Zur Pressemitteilung: t1p.de/67j4f
#Gesundheitsdaten #EHDS #Europa #Medizin #Arzneimittel #EUHTA
Aus Sicht der AWMF ist insbesondere die Qualität der Daten im EHDS entscheidend.
Zur Pressemitteilung: t1p.de/67j4f
#Gesundheitsdaten #EHDS #Europa #Medizin #Arzneimittel #EUHTA
December 4, 2025 at 1:06 PM
🩺 𝗘𝘂𝗿𝗼𝗽ä𝗶𝘀𝗰𝗵𝗲 𝗚𝗲𝘀𝘂𝗻𝗱𝗵𝗲𝗶𝘁𝘀𝗱𝗮𝘁𝗲𝗻 𝘂𝗻𝗱 𝗘𝗨-𝗡𝘂𝘁𝘇𝗲𝗻𝗯𝗲𝘄𝗲𝗿𝘁𝘂𝗻𝗴: 𝗪𝗶𝗲 𝗽𝗿𝗼𝗳𝗶𝘁𝗶𝗲𝗿𝗲𝗻 𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝗶𝗻𝗻𝗲𝗻 𝘂𝗻𝗱 𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝗲𝗻?
Aus Sicht der AWMF ist insbesondere die Qualität der Daten im EHDS entscheidend.
Zur Pressemitteilung: t1p.de/67j4f
#Gesundheitsdaten #EHDS #Europa #Medizin #Arzneimittel #EUHTA
Aus Sicht der AWMF ist insbesondere die Qualität der Daten im EHDS entscheidend.
Zur Pressemitteilung: t1p.de/67j4f
#Gesundheitsdaten #EHDS #Europa #Medizin #Arzneimittel #EUHTA
La implementación de la #EvaluaciónClínicaConjunta bajo la normativa #EUHTA plantea desafíos en el acceso a tratamientos para #enfermedades raras.
Accede al artículo completo de Félix Rubial en la revista #newsRare👇
bit.ly/4hPyLD9
Accede al artículo completo de Félix Rubial en la revista #newsRare👇
bit.ly/4hPyLD9
October 26, 2025 at 8:16 PM
La implementación de la #EvaluaciónClínicaConjunta bajo la normativa #EUHTA plantea desafíos en el acceso a tratamientos para #enfermedades raras.
Accede al artículo completo de Félix Rubial en la revista #newsRare👇
bit.ly/4hPyLD9
Accede al artículo completo de Félix Rubial en la revista #newsRare👇
bit.ly/4hPyLD9
6 months from CE marking to JCA dossier submission? That’s the timeline proposed in the draft Implementing Regulation, and it’s raising alarms. Our article explores why this compressed schedule is misaligned with RWE generation for medical devices: buff.ly/tZL1r9Z #EUHTA
October 22, 2025 at 11:02 AM
6 months from CE marking to JCA dossier submission? That’s the timeline proposed in the draft Implementing Regulation, and it’s raising alarms. Our article explores why this compressed schedule is misaligned with RWE generation for medical devices: buff.ly/tZL1r9Z #EUHTA
European Commission adopts final implementing regulation for #JointClinicalAssessments under the #EUHTA framework | Becaris Publishing becarispublishing.com/digital-cont...
European Commission adopts final implementing regulation for joint clinical assessments under the EU HTA framework | Becaris Publishing
becarispublishing.com
October 20, 2025 at 3:24 PM
European Commission adopts final implementing regulation for #JointClinicalAssessments under the #EUHTA framework | Becaris Publishing becarispublishing.com/digital-cont...
Our recent white paper highlights the role of RWE in JCA guidelines and our advice for companies utilizing RWE for JCA submissions. Read our latest paper for more information at buff.ly/BB9K5nW
#JCA #EUHTA #ATMP #RWE #JCAFramework #HTA #EUHTA
#JCA #EUHTA #ATMP #RWE #JCAFramework #HTA #EUHTA
October 3, 2025 at 3:03 PM
Our recent white paper highlights the role of RWE in JCA guidelines and our advice for companies utilizing RWE for JCA submissions. Read our latest paper for more information at buff.ly/BB9K5nW
#JCA #EUHTA #ATMP #RWE #JCAFramework #HTA #EUHTA
#JCA #EUHTA #ATMP #RWE #JCAFramework #HTA #EUHTA
La implementación de la #EvaluaciónClínicaConjunta bajo la normativa #EUHTA plantea desafíos en el acceso a tratamientos para #enfermedades raras.
Accede al artículo completo de Félix Rubial en la revista #newsRare👇
bit.ly/4hPyLD9
Accede al artículo completo de Félix Rubial en la revista #newsRare👇
bit.ly/4hPyLD9
September 14, 2025 at 7:16 PM
La implementación de la #EvaluaciónClínicaConjunta bajo la normativa #EUHTA plantea desafíos en el acceso a tratamientos para #enfermedades raras.
Accede al artículo completo de Félix Rubial en la revista #newsRare👇
bit.ly/4hPyLD9
Accede al artículo completo de Félix Rubial en la revista #newsRare👇
bit.ly/4hPyLD9
In our new white paper, we highlight the role of RWE in JCA guidelines and our advice for companies utilizing RWE for JCA submissions. Read our latest paper for more information at buff.ly/BB9K5nW
#JCA #EUHTA #ATMP #RWE #JCAFramework #HTA #EUHTA
#JCA #EUHTA #ATMP #RWE #JCAFramework #HTA #EUHTA
September 11, 2025 at 11:10 AM
In our new white paper, we highlight the role of RWE in JCA guidelines and our advice for companies utilizing RWE for JCA submissions. Read our latest paper for more information at buff.ly/BB9K5nW
#JCA #EUHTA #ATMP #RWE #JCAFramework #HTA #EUHTA
#JCA #EUHTA #ATMP #RWE #JCAFramework #HTA #EUHTA
Regina Skavron: EU-HTA in einer Minute
Die europäischen #nutzenbewertungen (#euhta) starten 2025. Regina Skavron, Bereichsleiterin "Methodik und Koordination der europäischen Nutzenbewertung von Arzneimitteln" im IQWiG, erklärt kurz und knapp, worum es geht.
Die europäischen #nutzenbewertungen (#euhta) starten 2025. Regina Skavron, Bereichsleiterin "Methodik und Koordination der europäischen Nutzenbewertung von Arzneimitteln" im IQWiG, erklärt kurz und knapp, worum es geht.
September 8, 2025 at 11:27 AM
Regina Skavron: EU-HTA in einer Minute
Die europäischen #nutzenbewertungen (#euhta) starten 2025. Regina Skavron, Bereichsleiterin "Methodik und Koordination der europäischen Nutzenbewertung von Arzneimitteln" im IQWiG, erklärt kurz und knapp, worum es geht.
Die europäischen #nutzenbewertungen (#euhta) starten 2025. Regina Skavron, Bereichsleiterin "Methodik und Koordination der europäischen Nutzenbewertung von Arzneimitteln" im IQWiG, erklärt kurz und knapp, worum es geht.
La implementación de la #EvaluaciónClínicaConjunta bajo la normativa #EUHTA plantea desafíos en el acceso a tratamientos para #enfermedades raras.
Accede al artículo completo de Félix Rubial en la revista #newsRare👇
bit.ly/4hPyLD9
Accede al artículo completo de Félix Rubial en la revista #newsRare👇
bit.ly/4hPyLD9
August 3, 2025 at 7:16 PM
La implementación de la #EvaluaciónClínicaConjunta bajo la normativa #EUHTA plantea desafíos en el acceso a tratamientos para #enfermedades raras.
Accede al artículo completo de Félix Rubial en la revista #newsRare👇
bit.ly/4hPyLD9
Accede al artículo completo de Félix Rubial en la revista #newsRare👇
bit.ly/4hPyLD9